<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717626</url>
  </required_header>
  <id_info>
    <org_study_id>1000012140</org_study_id>
    <nct_id>NCT00717626</nct_id>
  </id_info>
  <brief_title>Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A</brief_title>
  <official_title>Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the feasibility of a large-scale clinical&#xD;
      trial of once-daily prophylaxis. The secondary objectives are to collect clinical efficacy&#xD;
      outcomes so that we can better plan a large-scale study; we will estimate the effect size and&#xD;
      variability of effect and resource utilization of once-daily prophylaxis to allow us to set a&#xD;
      sample size for a definitive trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia is an important and costly disorder; if left untreated, it may have serious&#xD;
      consequences. The greatest impact of hemophilia occurs from recurrent bleeding into joints.&#xD;
      The consequences of joint bleeding include pain associated with acute bleeding and later&#xD;
      chronic arthropathy. Half of affected children with severe hemophilia have joint damage;&#xD;
      joint damage is more frequent with increased bleeding. The prevention and treatment of&#xD;
      bleeding is very expensive and therefore finding a cost-effective treatment is of high&#xD;
      priority.&#xD;
&#xD;
      Worldwide, two major treatment strategies have been used to prevent arthropathy - on demand&#xD;
      therapy and factor prophylaxis. The goal of prophylaxis is to convert the severe to the&#xD;
      moderate phenotype by providing circulating factor activity of greater than 1%. Patients with&#xD;
      greater than 1% circulating factor VIII activity rarely have spontaneous hemarthroses.&#xD;
      Therefore, the goal of providing circulating factor at this level is to eliminate spontaneous&#xD;
      hemarthroses. The term primary prophylaxis suggests using preventative factor VIII&#xD;
      replacement from a very early age. The term secondary prophylaxis is used to describe the&#xD;
      application of prophylaxis at a later disease stage. In this study, secondary prophylaxis&#xD;
      will be used.&#xD;
&#xD;
      Once-daily prophylaxis is a novel application of hemophilia factor prophylaxis for youth and&#xD;
      young adults. Before embarking on a costly definitive trial we feel that it is necessary to&#xD;
      demonstrate that subjects will be willing to enroll and will be compliant with the therapy.&#xD;
      Moreover, we need to establish an estimate of the effect of once-daily prophylaxis on&#xD;
      bleeding rates, quality of life, and joint damage progression in order to design a definitive&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemophilia Joint Health Score (HJHS) 2.0</measure>
    <time_frame>4 months, 12 months</time_frame>
    <description>Tool developed to assess joint health in persons with hemophilia (PWH) through several assessments of 9 items in the 6 index joints (elbows, knees, and ankles). It has been internationally validated and has demonstrated inter-observer and test-retest reliability supporting its use as an effective physical examination assessment tool for PWH.&#xD;
Range: 0 - 124 ( Best score = 0, Worst score = 124)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independence Score in Hemophilia (FISH)</measure>
    <time_frame>4 months, 12 months</time_frame>
    <description>Tool for assessment of 8 areas of musculoskeletal (MSK) function in patients with hemophlia.&#xD;
Range: 0 - 32 ( Best score = 0, Worst score = 32)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL Transformed Z-Score (Includes the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) and Haemo-QoL A)</measure>
    <time_frame>4 months, 12 months</time_frame>
    <description>Canadian Haemophilia Outcomes-Kids Life Assessment Tool is a validated 35-item disease specific measure of Quality of Life in boys with hemophilia ages 4 - 17 yrs. Range: 0 - 100 ( Best score = 100, Worst score = 0)&#xD;
The Adult Haemo-QoL Questionnaire is a validated disease specific measure of Quality of Life in adults with hemophilia ages &gt; 18 yrs. It is a 41-item questionnaire that considers how hemophilia affects 4 specific areas of their life. These areas include day-to-day activities, moods &amp; feelings, work or school life, family life &amp; social life, and hemophilia treatment. Range: 0 - 100 ( Best score = 0, Worst score = 100)&#xD;
The two measures were transformed into a Z-score to enable comparison across both HRQoL scores. A score of 0 represents no difference between the means, whereas a positive z-score would indicate an improvement in HRQoL between baseline and end of study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM) . Version II</measure>
    <time_frame>4 months, 12 months</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (TSQM) is an 11-item questionnaire used to evaluate patient satisfaction when starting a new medication and/or treatment. The areas of Effectiveness, Side-Effects, Convenience, and Global Satisfaction are assessed. A modified version (approved by developers) of the questionnaire with the deletion of side effects was used fro the purpose of the study.&#xD;
Effectiveness, Convenience, and Global Satisfaction all include the Range: 0 - 100 ( Best score = 0, Worst score = 100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Previous Day Physical Activity Recall</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>The Previous Day Physical Activity Recall is a well-validated assessment of habitual physical activity. Activity was reported on 1 weekend day, and 2 weekdays.The intensity of the activity was recorded in Metabolic Equivalents (METs) and categorized as Light (&lt; 3.0 METs), Moderate (3.0 - 5.9 METs), Hard (6.0 - 8.9 METs), Very Hard (10.0 METs)&#xD;
Range: 0 - 10 METs per activity ( Best score = 10, Worst score = 0)&#xD;
MPA = Moderate Physical Activity VPA = Vigorous Physical Activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Index Joint Bleeds</measure>
    <time_frame>4, 8, and 12 months</time_frame>
    <description>The total number of index joint (elbows, knees, ankles) were extracted from the participant's (self-reported) diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Yearly Factor Consumption of FVIII Product on Low Dose Daily Prophylaxis</measure>
    <time_frame>12 months</time_frame>
    <description>The mean yearly factor consumption of FVIII product on low dose daily prophylaxis was collected for comparison against standard prophylaxis (High dose alternate day treatment). Patient diaries indicating the amount of factor VIII product taken per daily infusion was collected on study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Daily administration of low dose FVIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS</intervention_name>
    <description>Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
    <arm_group_label>Daily administration of low dose FVIII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe hemophilia A (&lt;1% factor VIII)&#xD;
&#xD;
          -  Age 12 to 24 years inclusive&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  No current factor VIII inhibitor (an inhibitor will be defined as ≥ 0.6 Bethesda&#xD;
             Units) within the past year&#xD;
&#xD;
          -  Able to participate in a home infusion program with adequate peripheral venous access&#xD;
             as assessed ny the treating investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Important co-morbidities (Acquired Immunodeficiency Syndrome or symptomatic HIV&#xD;
             infection, symptomatic hepatitis B or C infection)&#xD;
&#xD;
          -  Other concomitant acquired or congenital bleeding disorder (e.g. von Willebrand's&#xD;
             Disease)&#xD;
&#xD;
          -  Receiving factor VIII replacement through central venous catheter&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Feldman, MD,MSc,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <results_first_submitted>June 4, 2018</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Brian Feldman</investigator_full_name>
    <investigator_title>Division Head, Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Youth</keyword>
  <keyword>Young Adults</keyword>
  <keyword>Feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daily Administration of Low Dose FVIII</title>
          <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily Administration of Low Dose FVIII</title>
          <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemophilia Joint Health Score (HJHS) 2.0</title>
        <description>Tool developed to assess joint health in persons with hemophilia (PWH) through several assessments of 9 items in the 6 index joints (elbows, knees, and ankles). It has been internationally validated and has demonstrated inter-observer and test-retest reliability supporting its use as an effective physical examination assessment tool for PWH.&#xD;
Range: 0 - 124 ( Best score = 0, Worst score = 124)</description>
        <time_frame>4 months, 12 months</time_frame>
        <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemophilia Joint Health Score (HJHS) 2.0</title>
          <description>Tool developed to assess joint health in persons with hemophilia (PWH) through several assessments of 9 items in the 6 index joints (elbows, knees, and ankles). It has been internationally validated and has demonstrated inter-observer and test-retest reliability supporting its use as an effective physical examination assessment tool for PWH.&#xD;
Range: 0 - 124 ( Best score = 0, Worst score = 124)</description>
          <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="0.63" upper_limit="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional Independence Score in Hemophilia (FISH)</title>
        <description>Tool for assessment of 8 areas of musculoskeletal (MSK) function in patients with hemophlia.&#xD;
Range: 0 - 32 ( Best score = 0, Worst score = 32)</description>
        <time_frame>4 months, 12 months</time_frame>
        <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Independence Score in Hemophilia (FISH)</title>
          <description>Tool for assessment of 8 areas of musculoskeletal (MSK) function in patients with hemophlia.&#xD;
Range: 0 - 32 ( Best score = 0, Worst score = 32)</description>
          <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="-0.41" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL Transformed Z-Score (Includes the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) and Haemo-QoL A)</title>
        <description>Canadian Haemophilia Outcomes-Kids Life Assessment Tool is a validated 35-item disease specific measure of Quality of Life in boys with hemophilia ages 4 - 17 yrs. Range: 0 - 100 ( Best score = 100, Worst score = 0)&#xD;
The Adult Haemo-QoL Questionnaire is a validated disease specific measure of Quality of Life in adults with hemophilia ages &gt; 18 yrs. It is a 41-item questionnaire that considers how hemophilia affects 4 specific areas of their life. These areas include day-to-day activities, moods &amp; feelings, work or school life, family life &amp; social life, and hemophilia treatment. Range: 0 - 100 ( Best score = 0, Worst score = 100)&#xD;
The two measures were transformed into a Z-score to enable comparison across both HRQoL scores. A score of 0 represents no difference between the means, whereas a positive z-score would indicate an improvement in HRQoL between baseline and end of study.</description>
        <time_frame>4 months, 12 months</time_frame>
        <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>HRQoL Transformed Z-Score (Includes the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) and Haemo-QoL A)</title>
          <description>Canadian Haemophilia Outcomes-Kids Life Assessment Tool is a validated 35-item disease specific measure of Quality of Life in boys with hemophilia ages 4 - 17 yrs. Range: 0 - 100 ( Best score = 100, Worst score = 0)&#xD;
The Adult Haemo-QoL Questionnaire is a validated disease specific measure of Quality of Life in adults with hemophilia ages &gt; 18 yrs. It is a 41-item questionnaire that considers how hemophilia affects 4 specific areas of their life. These areas include day-to-day activities, moods &amp; feelings, work or school life, family life &amp; social life, and hemophilia treatment. Range: 0 - 100 ( Best score = 0, Worst score = 100)&#xD;
The two measures were transformed into a Z-score to enable comparison across both HRQoL scores. A score of 0 represents no difference between the means, whereas a positive z-score would indicate an improvement in HRQoL between baseline and end of study.</description>
          <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.64" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Satisfaction Questionnaire for Medication (TSQM) . Version II</title>
        <description>Treatment Satisfaction Questionnaire for Medication (TSQM) is an 11-item questionnaire used to evaluate patient satisfaction when starting a new medication and/or treatment. The areas of Effectiveness, Side-Effects, Convenience, and Global Satisfaction are assessed. A modified version (approved by developers) of the questionnaire with the deletion of side effects was used fro the purpose of the study.&#xD;
Effectiveness, Convenience, and Global Satisfaction all include the Range: 0 - 100 ( Best score = 0, Worst score = 100)</description>
        <time_frame>4 months, 12 months</time_frame>
        <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Questionnaire for Medication (TSQM) . Version II</title>
          <description>Treatment Satisfaction Questionnaire for Medication (TSQM) is an 11-item questionnaire used to evaluate patient satisfaction when starting a new medication and/or treatment. The areas of Effectiveness, Side-Effects, Convenience, and Global Satisfaction are assessed. A modified version (approved by developers) of the questionnaire with the deletion of side effects was used fro the purpose of the study.&#xD;
Effectiveness, Convenience, and Global Satisfaction all include the Range: 0 - 100 ( Best score = 0, Worst score = 100)</description>
          <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSQM Effectiveness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.41" lower_limit="-18.25" upper_limit="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSQM Convenience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" lower_limit="-14.08" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSQM Global Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.13" lower_limit="-14.89" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Previous Day Physical Activity Recall</title>
        <description>The Previous Day Physical Activity Recall is a well-validated assessment of habitual physical activity. Activity was reported on 1 weekend day, and 2 weekdays.The intensity of the activity was recorded in Metabolic Equivalents (METs) and categorized as Light (&lt; 3.0 METs), Moderate (3.0 - 5.9 METs), Hard (6.0 - 8.9 METs), Very Hard (10.0 METs)&#xD;
Range: 0 - 10 METs per activity ( Best score = 10, Worst score = 0)&#xD;
MPA = Moderate Physical Activity VPA = Vigorous Physical Activity</description>
        <time_frame>4 months and 12 months</time_frame>
        <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>The Previous Day Physical Activity Recall</title>
          <description>The Previous Day Physical Activity Recall is a well-validated assessment of habitual physical activity. Activity was reported on 1 weekend day, and 2 weekdays.The intensity of the activity was recorded in Metabolic Equivalents (METs) and categorized as Light (&lt; 3.0 METs), Moderate (3.0 - 5.9 METs), Hard (6.0 - 8.9 METs), Very Hard (10.0 METs)&#xD;
Range: 0 - 10 METs per activity ( Best score = 10, Worst score = 0)&#xD;
MPA = Moderate Physical Activity VPA = Vigorous Physical Activity</description>
          <population>Mean of differences between start of intervention (4 months) and end of study (12 months)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weekday 1 MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-2.24" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekday 1 VPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-3.65" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekday 2 MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-2.54" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekday 2 VPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5.1" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekend MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" lower_limit="-4.06" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weekend VPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="-1.76" upper_limit="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Yearly Factor Consumption of FVIII Product on Low Dose Daily Prophylaxis</title>
        <description>The mean yearly factor consumption of FVIII product on low dose daily prophylaxis was collected for comparison against standard prophylaxis (High dose alternate day treatment). Patient diaries indicating the amount of factor VIII product taken per daily infusion was collected on study.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Yearly Factor Consumption of FVIII Product on Low Dose Daily Prophylaxis</title>
          <description>The mean yearly factor consumption of FVIII product on low dose daily prophylaxis was collected for comparison against standard prophylaxis (High dose alternate day treatment). Patient diaries indicating the amount of factor VIII product taken per daily infusion was collected on study.</description>
          <units>International Units (IU)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211528" lower_limit="176125.79" upper_limit="246930.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Index Joint Bleeds</title>
        <description>The total number of index joint (elbows, knees, ankles) were extracted from the participant's (self-reported) diaries.</description>
        <time_frame>4, 8, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daily Administration of Low Dose FVIII</title>
            <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Index Joint Bleeds</title>
          <description>The total number of index joint (elbows, knees, ankles) were extracted from the participant's (self-reported) diaries.</description>
          <units>Bleeds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 months - Index joint bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 months - Index joint bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months - Index joint bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for a duration of 1 year.</time_frame>
      <desc>An adverse event log was maintained for each participant to identify and report any of the following:&#xD;
All-Cause Mortality&#xD;
Serious Adverse Events&#xD;
Other Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>Daily Administration of Low Dose FVIII</title>
          <description>Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)&#xD;
Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is &lt; 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brian Feldman</name_or_title>
      <organization>The Hospital for Sick Children</organization>
      <phone>416-813-5828</phone>
      <email>brian.feldman@sickkids.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

